The comparability tales: A phase-appropriate roadmap for CGT drug product development
American Society of Gene and Cell Therapy (ASGCT) CMC Committee Members, Nathalie Clément, Sadik H Kassim, Daniel Leblanc, Katy Spink, John Tomtishen · 2023
Read The comparability tales: A phase-appropriate roadmap for CGT drug product development by American Society of Gene and Cell Therapy (ASGCT) CMC Committee Members, Nathalie Clément, Sadik H Kassim, Daniel Leblanc, Katy Spink, John Tomtishen (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10805933.txt.
Description
Clément and colleagues, writing for a gene and cell therapy society committee in twenty twenty-three, set out a roadmap for comparability in cell and gene therapy products. Comparability means showing a product is still much the same after a change in how it is made. Such changes are common for these complex treatments.
The article sums up talks from the society's twenty twenty-three annual meeting. Speakers urged planning for changes early, using science-based checks, and asking for clearer rules from regulators. They favored studies planned ahead over studies done after the fact. Careful statistics and tracking of each product version also matter, they argued, for safe clinical and commercial growth.
Catalog record
| CREATOR | American Society of Gene and Cell Therapy (ASGCT) CMC Committee Members, Nathalie Clément, Sadik H Kassim, Daniel Leblanc, Katy Spink, John Tomtishen |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 10 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |